Koch Institute for Integrative Cancer Research at MIT.
The Koch Institute for Integrative Cancer Research at MIT harnesses MIT's interdisciplinary inquiry and technological innovation to accelerate cancer research. It focuses on producing knowledge and tools applicable broadly across various cancers, aiming to improve detection, monitoring, treatment, and prevention. The institute emphasizes collaboration across disciplines, including biology, engineering, chemistry, and computer science, to develop new technologies and treatments, with a strong commitment to translational research and community engagement.
Industries
Nr. of Employees
medium (51-250)
Koch Institute for Integrative Cancer Research at MIT.
500 Main Street, Building 76, Cambridge, MA 02139-4307
Products
Detection & Monitoring
We build tools and technologies to recognize and visualize cancer in its earliest stages along with novel devices that can track the development of tumors during and after treatment.
Metastasis
We investigate how cancer cells mutate and spread throughout the body, and devise new methods for identifying early transformations and intervening in this deadly process.
Immunology & Immunotherapy
We interrogate cancer's relationship with the immune system to understand mechanisms of immune evasion and suppression and develop immunotherapies that work for more patients and against more tumor types.
Nano-based Drugs
We work at the molecular level to engineer new therapeutic agents and drug delivery systems that can identify and target cancer cells and selectively destroy them.
Precision Medicine
We develop new strategies to pinpoint cancer’s vulnerabilities and overcome resistance by building a comprehensive understanding of the processes, signals, and mechanisms that determine a tumor’s response to treatment.
SBC Core Facilities
Core facility labs in the Robert A. Swanson Biotechnology Center offer cutting-edge equipment and specialized expertise to accelerate innovation and support investigations into key questions in cancer research.
Detection & Monitoring
We build tools and technologies to recognize and visualize cancer in its earliest stages along with novel devices that can track the development of tumors during and after treatment.
Metastasis
We investigate how cancer cells mutate and spread throughout the body, and devise new methods for identifying early transformations and intervening in this deadly process.
Immunology & Immunotherapy
We interrogate cancer's relationship with the immune system to understand mechanisms of immune evasion and suppression and develop immunotherapies that work for more patients and against more tumor types.
Nano-based Drugs
We work at the molecular level to engineer new therapeutic agents and drug delivery systems that can identify and target cancer cells and selectively destroy them.
Precision Medicine
We develop new strategies to pinpoint cancer’s vulnerabilities and overcome resistance by building a comprehensive understanding of the processes, signals, and mechanisms that determine a tumor’s response to treatment.
SBC Core Facilities
Core facility labs in the Robert A. Swanson Biotechnology Center offer cutting-edge equipment and specialized expertise to accelerate innovation and support investigations into key questions in cancer research.
Services
Shared instrumentation and technical services for genomics, imaging, and other advanced experimental methods through the Swanson Biotechnology Center core facilities.
Competitive internal program that provides funding and partnership support to interdisciplinary teams for translational cancer research in collaboration with external clinical partners.
Structured outreach offerings including gallery tours, school programs (Protein Program, Investigation Program, Cancer Research Program), and public exhibitions to communicate research and engage learners.
Conferences and thematic symposia that convene academic, clinical, and industry participants to present advances in areas such as antibody-drug conjugates, immune engineering, and precision cancer medicine.
Shared instrumentation and technical services for genomics, imaging, and other advanced experimental methods through the Swanson Biotechnology Center core facilities.
Competitive internal program that provides funding and partnership support to interdisciplinary teams for translational cancer research in collaboration with external clinical partners.
Structured outreach offerings including gallery tours, school programs (Protein Program, Investigation Program, Cancer Research Program), and public exhibitions to communicate research and engage learners.
Conferences and thematic symposia that convene academic, clinical, and industry participants to present advances in areas such as antibody-drug conjugates, immune engineering, and precision cancer medicine.
Expertise Areas
- Early detection and diagnostics
- Nanomedicine and drug delivery
- Cancer genetics and cellular programs
- Immunoengineering and immunotherapy research
Key Technologies
- Gene editing (CRISPR and related methods)
- Organoid models
- Nanoparticle-based delivery
- Single-cell RNA sequencing
News & Updates
Join us for the 23rd Annual Koch Institute Symposium to explore advancements in antibody drug conjugates as anti-cancer agents.
The Bridge Project supports interdisciplinary teams at MIT and Dana-Farber/Harvard Cancer Center working on translational cancer research. Proposals are due by October 14, 2025.
Companies can connect with the Koch Institute’s research community to shape the future of convergence science in oncology.
MIT postdoc Meaghan McGeary advocated for increased federal funding for cancer research in Washington, DC.
A Cell Systems paper identified mechanisms enabling resistance to cancer therapies, offering new intervention opportunities.
MIT alumni Victor Ambros and Gary Ruvkun shared the 2024 Nobel Prize in Physiology or Medicine for the discovery of microRNA and its role in gene regulation.
Join us for the 23rd Annual Koch Institute Symposium to explore advancements in antibody drug conjugates as anti-cancer agents.
The Bridge Project supports interdisciplinary teams at MIT and Dana-Farber/Harvard Cancer Center working on translational cancer research. Proposals are due by October 14, 2025.
Companies can connect with the Koch Institute’s research community to shape the future of convergence science in oncology.
MIT postdoc Meaghan McGeary advocated for increased federal funding for cancer research in Washington, DC.
A Cell Systems paper identified mechanisms enabling resistance to cancer therapies, offering new intervention opportunities.
MIT alumni Victor Ambros and Gary Ruvkun shared the 2024 Nobel Prize in Physiology or Medicine for the discovery of microRNA and its role in gene regulation.